Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Jun 23;16(6):e0252757.
doi: 10.1371/journal.pone.0252757. eCollection 2021.

Comparative performance and cycle threshold values of 10 nucleic acid amplification tests for SARS-CoV-2 on clinical samples

Affiliations
Comparative Study

Comparative performance and cycle threshold values of 10 nucleic acid amplification tests for SARS-CoV-2 on clinical samples

Miyuki Mizoguchi et al. PLoS One. .

Erratum in

Abstract

Background: A number of nucleic acid amplification tests (NAATs) for SARS-CoV-2 with different reagents have been approved for clinical use in Japan. These include research kits approved under emergency use authorization through simplified process to stabilize the supply of the reagents. Although these research kits have been increasingly used in clinical practice, limited data is available for the diagnostic performance in clinical settings.

Methods: We compared sensitivity, specificity, and cycle threshold (Ct) values obtained by NAATs using 10 kits approved in Japan including eight kits those receiving emergency use authorization using 69 frozen-stored clinical samples including 23 positive samples with various Ct values and 46 negative samples.

Results: Viral copy number of the frozen-stored samples determined with LightMix E-gene test ranged from 0.6 to 84521.1 copies/μL. While no false-positive results were obtained by any of these tests (specificity: 100% [95% CI, 88.9%-100%]), sensitivity of the nine tests ranged from 68.2% [95% CI, 45.1%-86.1%] to 95.5% [95% CI, 77.2%-99.9%] using LightMix E-gene test as the gold standard. All tests showed positive results for all samples with ≥100 copies/μL. Significant difference of Ct values even among tests amplifying the same genetic region (N1-CDC, N2) was also observed.

Conclusion: Difference in the diagnostic performance was observed among NAATs approved in Japan. Regarding diagnostic kits for emerging infectious diseases, a system is needed to ensure both rapidity of reagent supply and accuracy of diagnosis. Ct values, which are sometimes regarded as a marker of infectivity, are not interchangeable when obtained by different assays.

PubMed Disclaimer

Conflict of interest statement

Sohei Harada (SH) reports personal fees from BD, Meiji, Shionogi, Sumitomo Dainippon Pharma, MSD, Astellas, Beckman Coulter Diagnostics, FUJIFILM Toyama Chemical, Daiichi Sankyo, and NISSUI PHARMACEUTICAL, and grants from MSD, outside the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors declare no conflict of interest.

Figures

Fig 1
Fig 1. Calibration curve of LightMix E-gene test.
Fig 2
Fig 2. Cycle threshold values obtained by NAATs amplifying (a) N-NIID, (b) N1-CDC, (c) N2, and (d) N1-CDC/N2.
The combinations of tests that showed statistically significant differences in cycle threshold values are indicated by brackets with asterisks at the right end. Cycle threshold values obtained by LightMix E-gene test were plotted in all graphs as references.

Similar articles

Cited by

References

    1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–154. doi: 10.1038/s41579-020-00459-7 - DOI - PMC - PubMed
    1. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al.. Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019 (nCoV-2019) in Japan. Jpn J Infect Dis. 2020;73(4):304–307. doi: 10.7883/yoken.JJID.2020.061 - DOI - PubMed
    1. Matsumura Y, Shimizu T, Noguchi T, Nakano S, Yamamoto M, Nagao M. Comparison of 12 Molecular Detection Assays for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). J Mol Diagn. 2021;23(2):164–170. doi: 10.1016/j.jmoldx.2020.11.007 - DOI - PMC - PubMed
    1. Kanda Y. Investigation of the freely available easy-to-use software ’EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8. doi: 10.1038/bmt.2012.244 - DOI - PMC - PubMed
    1. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al.. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 2020;382(22):2081–2090. doi: 10.1056/NEJMoa2008457 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances